Roivant Sciences

Roivant Sciences is owned by Sumitomo Chemical.

Sumitomo Chemical is one of the...

• Forbes Global 2000 (#1009);
• Nikkei 225;
• Topix.

Sumitomo Chemical is a company listed under the stock ticker 4005 (JP).

Sumitomo Chemical has a direct presence in 6 countries.

Sumitomo Chemical has 28 subsidiaries including Asahi Chemical, Ciox Health and Covant Therapeutics.

They are in:

• Biotechnology55%
• Chemicals24%
• Other21%

View the org chart displaying its 301 main executives

Most searched biographies at Roivant Sciences

• Matthew Gline, Chief Executive Officer
• James Momtazee, Director
• Melissa Epperly, Director

Popular executive movements at Roivant Sciences

• Mayukh Sukhatme who was Chief Investment Officer and President, becomes Director, Chief Investment Officer and President  (posted on November 10 2023).
• Hiroshi Nomura, Director, will leave the company on Aug. 31, 2023  (posted on August 7 2023).

Create your alert
to follow the executive moves at Roivant Sciences.

Sumitomo Chemical has 2,277 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and Adaptive Phage Therapeutics (United States (USA)).

Popular M&A news in Biotechnology

• Histogen has filed for bankruptcy protection  (posted on April 19 2024).
• Bruker has announced the acquisition of NanoString Technologies  (posted on April 18 2024).
• Vertex Pharmaceuticals has announced the acquisition of Alpine Immune Sciences  (posted on April 16 2024).

Popular contacts in Biotechnology

• Ali Behbahani - Non-Executive Director at Adaptimmune Therapeutics
• Vik Bajaj - Director at Interline Therapeutics
• Khalil Barrage - Interim Chairman of the Board at Sensorion

Learn more about the Biotechnology industry >

Press releases by Roivant Sciences

• There's A Paradigm Shift In Immunology; And Big Pharma Is Paying Richly For It
• JPM Day 3 had a cautiously optimistic outlook
• Roivant’s Matt Gline on raising capital and biotech’s outlook for 2024
• Immunovant stock gains after data for autoimmune therapy
• Roche Enters Into a Definitive Agreement to Acquire Telavant Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease From Roivant | Roivant Sciences Ltd.
• Roivant Sciences to Report Financial Results for the Quarter Ended June 30, 2022 on Monday, August 15, 2022 | Roivant Sciences Ltd.
• Roivant and Pfizer Unveil Priovant Therapeutics and Ongoing Registrational Studies for Oral Brepocitinib in Dermatomyositis and Lupus | Roivant Sciences Ltd.
• Roivant Sciences Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2022 and Provides Business Update | Roivant Sciences Ltd.
• Roivant Sciences to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2022 on Tuesday, June 28, 2022 | Roivant Sciences Ltd.
• FDA Approves Dermavant’s VTAMA® (tapinarof) cream, 1% for the Treatment of Plaque Psoriasis in Adults: First Topical Novel Chemical Entity Launched for Psoriasis in the U.S. in 25 Years | Roivant Sciences Ltd.
• View more press releases Close

Social media about Roivant Sciences

• Roivant Sciences on Wikipedia, Google News & Yahoo Finance
• Roivant Sciences on LinkedIn, Twitter & YouTube

Contact by email its executives including Matthew Gline

Call Roivant Sciences at +41 43...

View the org chart

Register to receive your alert

Report an error